Thèrése Bocklage
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thèrése Bocklage has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Alissa Greenbaum
University of New Mexico Comprehensive Cancer Center, Albuquerque, USA
1 shared publication - Ashwani Rajput
Division of Surgical Oncology, Department of Surgery, University of New Mexico, Albuquerque, NM; University of New Mexico Comprehensive Cancer Center, Albuquerque, NM
1 shared publication - Ben Liem
Comprehensive Cancer Center, University of New Mexico, Albuquerque, NM, USA
1 shared publication - Berndt Schmit
Department of Radiology, University of Pittsburgh Medical Center East, Pittsburgh, PA 15146, USA
1 shared publication - Claire F. Verschraegen
Division of Medical Oncology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH 43210, USA
1 shared publication G. Olson
Division of Otolaryngology, Department of Surgery, University of New Mexico School of Medicine (UNM SOM), Albuquerque, NM, USA
1 shared publication
Latest Publications
- Open Access
- 1 September 2017
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 16 (3) , e165-e170
Mutant-Allele Tumor Heterogeneity Scores Correlate With Risk of Metastases in Colon Cancer
- 1 September 2017
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 16 (3) , e165-e170
Open AccessMutant-Allele Tumor Heterogeneity Scores Correlate With Risk of Metastases in Colon Cancer
- 15 September 2016
- Published by Springer Nature in Head and Neck Pathology
- Vol. 11 (2) , 264-265
Regarding Dettloff et al. “Mammary Analog Secretory Carcinoma (MASC) Involving the Thyroid Gland: A Report of the First Three Cases”
- 15 September 2016
- Published by Springer Nature in Head and Neck Pathology
- Vol. 11 (2) , 264-265
Regarding Dettloff et al. “Mammary Analog Secretory Carcinoma (MASC) Involving the Thyroid Gland: A Report of the First Three Cases”
- 13 April 2016
- Published by Springer Nature in Head and Neck Pathology
- Vol. 10 (3) , 405-413
A Case of Primary Mammary Analog Secretory Carcinoma (MASC) of the Thyroid Masquerading as Papillary Thyroid Carcinoma: Potentially More than a One Off
We present the second reported mammary analog secretory carcinoma (MASC) apparently arising in the thyroid and propose a potential close relationship to ETV6-NTRK3 fusion papillary thyroid carcinoma. The patient, a 36 year old woman, presented with a neck mass of 1 year’s duration. Imaging studies showed a tumor involving most of the thyroid with enlarged regional lymph nodes. FNA biopsy yielded a diagnosis of “papillary thyroid carcinoma”. Resection revealed a 4.5 cm infiltrative tumor. Final diagnosis was “papillary thyroid carcinoma (PTC) consistent with diffuse sclerosing variant” with positive lymph nodes (2+/4) and margins. Histologic features included mixed microcystic, solid, follicular and papillary architecture, prominent nucleoli, abundant nuclear grooves and rare nuclear pseudo-inclusions. Despite radioactive iodine, radiotherapy and multiagent chemotherapy, the patient progressed over 6 years with local recurrence and additional lymph node involvement finally developing widespread distant metastases. Prompted by the breast carcinoma-like histopathology of a metastasis, immunohistochemical staining was performed and revealed strong expression of GATA3 and mammaglobin with no reactivity for thyroglobulin or TTF-1. The original tumor was then tested and showed the same immunoprofile. RT-PCR confirmed the presence of an ETV6-NTRK3 fusion consistent with a diagnosis of MASC. Our patient’s clinical, imaging and morphologic features remarkably mimicked papillary thyroid carcinoma. At the molecular level, the ETV6-NTRK3 fusion in this patient involved exons reported in the rare “papillary thyroid carcinoma” with this translocation. Given the immunophenotype of this case, it is possible that at least some ETV6-NTRK3 fusion positive PTC are actually MASC masquerading as papillary thyroid carcinoma.
- 13 April 2016
- Published by Springer Nature in Head and Neck Pathology
- Vol. 10 (3) , 405-413
A Case of Primary Mammary Analog Secretory Carcinoma (MASC) of the Thyroid Masquerading as Papillary Thyroid Carcinoma: Potentially More than a One Off
We present the second reported mammary analog secretory carcinoma (MASC) apparently arising in the thyroid and propose a potential close relationship to ETV6-NTRK3 fusion papillary thyroid carcinoma. The patient, a 36 year old woman, presented with a neck mass of 1 year’s duration. Imaging studies showed a tumor involving most of the thyroid with enlarged regional lymph nodes. FNA biopsy yielded a diagnosis of “papillary thyroid carcinoma”. Resection revealed a 4.5 cm infiltrative tumor. Final diagnosis was “papillary thyroid carcinoma (PTC) consistent with diffuse sclerosing variant” with positive lymph nodes (2+/4) and margins. Histologic features included mixed microcystic, solid, follicular and papillary architecture, prominent nucleoli, abundant nuclear grooves and rare nuclear pseudo-inclusions. Despite radioactive iodine, radiotherapy and multiagent chemotherapy, the patient progressed over 6 years with local recurrence and additional lymph node involvement finally developing widespread distant metastases. Prompted by the breast carcinoma-like histopathology of a metastasis, immunohistochemical staining was performed and revealed strong expression of GATA3 and mammaglobin with no reactivity for thyroglobulin or TTF-1. The original tumor was then tested and showed the same immunoprofile. RT-PCR confirmed the presence of an ETV6-NTRK3 fusion consistent with a diagnosis of MASC. Our patient’s clinical, imaging and morphologic features remarkably mimicked papillary thyroid carcinoma. At the molecular level, the ETV6-NTRK3 fusion in this patient involved exons reported in the rare “papillary thyroid carcinoma” with this translocation. Given the immunophenotype of this case, it is possible that at least some ETV6-NTRK3 fusion positive PTC are actually MASC masquerading as papillary thyroid carcinoma.
- Open Access
A Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
MTOR inhibitors are emerging as important anti-neoplastic agents with a wide range of clinical applications. The topoisomerase I inhibitor irinotecan is a potent DNA damaging drug, with a broad spectrum of anticancer activities. mTOR appears to enhance cancer cell survival following DNA damage, thus the inhibition of mTOR after irinotecan could theoretically show synergistic activities in patients. Both mTOR inhibitors and irinotecan have been used as single agents in soft tissue sarcomas with limited efficacy. We completed a phase I trial of the combination of the mTOR inhibitor, temsirolimus, and irinotecan in patients with advanced soft tissue sarcoma. Seventeen patients were recruited. The Phase II recommended dose is 20 mg of temsirolimus and 80 mg/m2 of irinotecan administered on weekly basis for three out of four weeks. Most frequently encountered toxicities include cytopenias, fatigue, and gastrointestinal toxicities. Two patients (one with leiomyosarcoma and one with high grade undifferentiated sarcoma) had stable disease for more than 12 months.
Open AccessA Phase I Study of the Combination of Temsirolimus with Irinotecan for Metastatic Sarcoma
MTOR inhibitors are emerging as important anti-neoplastic agents with a wide range of clinical applications. The topoisomerase I inhibitor irinotecan is a potent DNA damaging drug, with a broad spectrum of anticancer activities. mTOR appears to enhance cancer cell survival following DNA damage, thus the inhibition of mTOR after irinotecan could theoretically show synergistic activities in patients. Both mTOR inhibitors and irinotecan have been used as single agents in soft tissue sarcomas with limited efficacy. We completed a phase I trial of the combination of the mTOR inhibitor, temsirolimus, and irinotecan in patients with advanced soft tissue sarcoma. Seventeen patients were recruited. The Phase II recommended dose is 20 mg of temsirolimus and 80 mg/m2 of irinotecan administered on weekly basis for three out of four weeks. Most frequently encountered toxicities include cytopenias, fatigue, and gastrointestinal toxicities. Two patients (one with leiomyosarcoma and one with high grade undifferentiated sarcoma) had stable disease for more than 12 months.
- 1 January 2000
- Published by Wiley in Diagnostic Cytopathology
- Vol. 22 (1) , 39-44
Specimen fine-needle aspiration cytology of littoral cell angioma with histologic and immunohistochemical confirmation
We performed a specimen fine-needle aspiration biopsy (FNAB) of a littoral cell angioma (LCA) from a 33-yr-old male who underwent elective splenectomy due to thrombocytopenia secondary to Wiscott-Aldrich syndrome. Gross examination revealed a 420-g, diffusely enlarged spleen which contained two moderately well-circumscribed, soft brown lesions measuring 0.3 and 1.0 cm, respectively. Benchtop aspiration of the lesions following splenectomy yielded a cellular sample composed predominantly of dispersed single cells, which ranged from columnar to spindle to circariform in shape. Nuclei were round to oval with even chromatin, and many contained single longitudinal grooves. A majority of the cells contained abundant, granular hemosiderin pigment, a key cytologic feature. Immunohistochemical staining revealed reactivity for antibodies to CD68 and factor VIII-related antigen with no reactivity for S-100 protein and CD8. Littoral cell angioma must be differentiated from splenic hamartoma, hemangioma, angiosarcoma, littoral cell angiosarcoma, and epithelioid and spindle cell hemangioendothelioma. A combination of cytologic features and immunohistochemical results should enable an accurate diagnosis. Diagn. Cytopathol. 2000;22:39–44.
- 1 January 2000
- Published by Wiley in Diagnostic Cytopathology
- Vol. 22 (1) , 39-44
Specimen fine-needle aspiration cytology of littoral cell angioma with histologic and immunohistochemical confirmation
We performed a specimen fine-needle aspiration biopsy (FNAB) of a littoral cell angioma (LCA) from a 33-yr-old male who underwent elective splenectomy due to thrombocytopenia secondary to Wiscott-Aldrich syndrome. Gross examination revealed a 420-g, diffusely enlarged spleen which contained two moderately well-circumscribed, soft brown lesions measuring 0.3 and 1.0 cm, respectively. Benchtop aspiration of the lesions following splenectomy yielded a cellular sample composed predominantly of dispersed single cells, which ranged from columnar to spindle to circariform in shape. Nuclei were round to oval with even chromatin, and many contained single longitudinal grooves. A majority of the cells contained abundant, granular hemosiderin pigment, a key cytologic feature. Immunohistochemical staining revealed reactivity for antibodies to CD68 and factor VIII-related antigen with no reactivity for S-100 protein and CD8. Littoral cell angioma must be differentiated from splenic hamartoma, hemangioma, angiosarcoma, littoral cell angiosarcoma, and epithelioid and spindle cell hemangioendothelioma. A combination of cytologic features and immunohistochemical results should enable an accurate diagnosis. Diagn. Cytopathol. 2000;22:39–44.